Punto de vista del analista
La administración transmucosa de fármacos implica membranas mucosas como la mucosa oral, la mucosa nasal, la mucosa rectal, la mucosa vaginal y la mucosa ocular. mucosa y mucosa pulmonar para la administración de fármacos. Una mayor biodisponibilidad, un rápido inicio de acción, la evasión del metabolismo de primer paso y la facilidad de administración son las ventajas clave de este sistema de administración de fármacos sobre las rutas tradicionales de administración de fármacos. El informe incluye perspectivas de crecimiento debido a las tendencias actuales del mercado de sistemas de administración de medicamentos transmucosos y su impacto previsible durante el período de pronóstico.
Factores que impulsan el crecimiento del mercado de sistemas de administración de medicamentos transmucosos
La administración de medicamentos transmucosa es una de las preferidas vía de administración del fármaco debido a la eficacia sostenida de este tipo de administración. Las vías transmucosas, como la intranasal, bucal, sublingual y rectal, son métodos no invasivos de administración sistémica de fármacos. Son particularmente útiles ya que los cuidadores o los pacientes pueden administrar estos medicamentos sin necesidad de personal experto. Además, un rápido inicio de acción con un metabolismo de primer paso reducido los hace ideales para cuidados paliativos y al final de la vida. Actúan rápidamente para aliviar los síntomas y ofrecer a los pacientes un alivio rápido. Como resultado, los sistemas de administración transmucosa se han convertido en una opción popular en el tratamiento de diversas enfermedades crónicas, como enfermedades cardiovasculares, diabetes y enfermedades respiratorias crónicas. Según un artículo publicado por PubMed Central en enero de 2020, se llevó a cabo un estudio para la investigación y comparación de la seguridad y farmacocinética de la dihidroergotamina (DHE) cuando se administra en forma de polvo de DHE intranasal (STS101), aerosol de DHE intranasal (Migranal ) e inyección intramuscular (IM) de DHE en sujetos sanos. El estudio concluyó que STS101 es un tratamiento agudo para la migraña, fácil de administrar, no inyectado, con un perfil de tolerabilidad favorable. Además, se espera que facilite un alivio rápido y constante del dolor y suprima los síntomas de la migraña sin recurrencia.
Se ofrecen numerosos fármacos farmacológicos como formaciones transmucosas orales; estos incluyen agentes cardiovasculares, sedantes y analgésicos. Las películas orales biodegradables ayudan en la administración de fármacos a la circulación sistémica, lo que resulta muy ventajoso para personas con disfagia, vómitos repetidos, hipertensión, ataques cardíacos, asma, náuseas, parálisis y trastornos mentales. Estas películas orales de rápida disolución son finas tiras adhesivas que se colocan en la lengua del paciente o en cualquier tejido de la mucosa oral.
Por lo tanto, ventajas como la facilidad de administración, la alta biodisponibilidad, la disponibilidad sistémica del fármaco y la rápida acción impulsan el Crecimiento del mercado de Sistemas de administración de fármacos transmucosos.
Perspectivas estratégicas
Segmentación y alcance del informe
El “Análisis del mercado global de Sistemas de administración de fármacos transmucosos hasta 2031” es un estudio especializado y en profundidad. Estudio de la industria farmacéutica con especial enfoque en el análisis de tendencias del mercado global. El informe tiene como objetivo proporcionar una descripción general del mercado con una segmentación detallada del mercado basada en sistemas, usuarios finales y geografía. Proporciona estadísticas clave sobre los principales actores del mercado y menciona tendencias y oportunidades clave que prevalecen en el mercado. El alcance del informe del mercado global de sistemas de administración de medicamentos transmucosos incluye América del Norte (EE. UU., Canadá y México), Europa (Alemania, Francia, Italia, Reino Unido, España y resto de Europa), Asia Pacífico (China, Japón, India, Australia, Corea del Sur y el resto de Asia Pacífico), Medio Oriente y África (Sudáfrica, Arabia Saudita, Emiratos Árabes Unidos y el resto de Medio Oriente y África) y América del Sur y Central (Brasil, Argentina y el resto de América del Sur y Centroamérica).
Perspectivas basadas en sistemas
Basado en sistemas, el mercado se segmenta en nasopulmonar, bucal y sublingual, vaginal y otros. El segmento nasopulmonar tuvo la mayor participación de mercado de sistemas de administración de fármacos transmucosos en 2023 y se prevé que registre la CAGR más alta de 2023 a 2031.
Información basada en el usuario final
Basado en el usuario final, el El mercado está segmentado en centros de atención médica, entornos de atención domiciliaria y otros. El segmento de instalaciones sanitarias tuvo la mayor cuota de mercado en 2023. Esto puede atribuirse a la disponibilidad de mejores instalaciones y médicos capacitados en los hospitales. Además, se prevé que el segmento de entornos de atención domiciliaria tenga la CAGR más alta de 2023 a 2031.
Mercado de sistemas de administración de fármacos transmucosos, por usuario final – 2023 y 2031
Análisis regional
Según la geografía, el mercado está segmentado principalmente en América del Norte, Asia Pacífico, Europa, Medio Oriente y África, y América del Sur y Central. En términos de ingresos, América del Norte tuvo la mayor cuota de mercado de sistemas de administración de fármacos transmucosos en 2023. Estados Unidos domina el mercado en esta región. Esto se puede atribuir al aumento de casos de enfermedades crónicas como diabetes, asma y enfermedades cardíacas, así como al creciente número de lanzamientos de productos por parte de actores clave.
Desarrollos de la industria y oportunidades futuras:
El pronóstico del mercado de sistemas de administración de medicamentos transmucosos puede ayudar a las partes interesadas en este mercado a planificar sus estrategias de crecimiento. Según los comunicados de prensa de la empresa, a continuación se enumeran algunos desarrollos estratégicos de los principales actores que operan en el mercado global:
•En febrero de 2024, Aquestive Therapeutics, Inc. presentó un cartel en la Academia Estadounidense de Alergia. Reunión anual de 2024 sobre Asma e Inmunología (AAAAI) en Washington, DC, que destaca los datos farmacocinéticos (PK) y farmacodinámicos (PD) positivos de dos estudios clínicos completos sobre películas sublinguales de Anaphylm (epinefrina). En agosto de 2022, iX Biopharma. Ltd lanzó IXB-322, un nuevo programa para ampliar su cartera. El programa tiene como objetivo desarrollar una oblea de dexmedetomidina sublingual para el tratamiento de la agitación en la demencia y otras indicaciones. Esta iniciativa es parte de la estrategia de iX Biopharma para reutilizar los medicamentos aprobados existentes utilizando su tecnología patentada de plataforma de administración de medicamentos WaferiX. En mayo de 2021, Tillotts Pharma AG, parte del grupo japonés Zeria, agregó un nuevo medicamento a su cartera de gastroenterología con el lanzamiento de AsacolTM 1g (mesalazina). El supositorio de alta potencia se usa para tratar los síntomas de proctitis ulcerosa de leves a moderados en adultos. Este lanzamiento ayudará a la empresa a ofrecer terapias innovadoras a pacientes con enfermedades gastrointestinales. Los supositorios AsacolTM 1g brindan una forma conveniente de tratamiento para personas que sufren de proctitis ulcerosa, ya que solo requieren una única dosis diaria. En abril de 2021, Teva Pharmaceuticals USA, Inc., una filial estadounidense de Teva Pharmaceutical Industries Ltd., anunció el lanzamiento de su versión genérica del medicamento en supositorios Casana 1 (mesalamina). El medicamento está indicado para el tratamiento de la proctitis ulcerosa activa (colitis ulcerosa rectal) en los EE. UU. Teva Pharmaceutical Industries Ltd; Corporación Cigna.; BioDelivery Sciences Internacional, Inc; 3M; Henkel Finlandia Oy; GlaxoSmithKline plc; Aquestive Therapeutics, Inc; Camurus AB; Ximédica; y Noven Pharmaceuticals, Inc son algunas de las empresas clave descritas en el informe de mercado de sistemas de administración de medicamentos transmucosos. Estos actores líderes se centran en expandir y diversificar su presencia en el mercado y su clientela, aprovechando las oportunidades comerciales en el mercado.
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
The transmucosal drug delivery involves mucosal membranes such as oral mucosa, nasal mucosa, rectal mucosa, vaginal mucosa, ocular mucosa, and pulmonary mucosa for drug administration. Higher bioavailability, rapid onset of action, evasion of first-pass metabolism, and ease of administration are the key advantages of this drug delivery system over traditional routes of drug administration.
Key factors driving the transmucosal drug delivery systems market growth is rising adoption of drug delivery systems for disease management and the development of new drug molecules and biological formulations.
The transmucosal drug delivery systems market was valued at US$ 80.21 billion in 2023.
The transmucosal drug delivery systems market majorly consists of the players, including Teva Pharmaceutical Industries Ltd; Cigna Corporation.; BioDelivery Sciences International, Inc; 3M; Henkel Finland Oy; GlaxoSmithKline plc; Aquestive Therapeutics, Inc; Camurus AB; Ximedica; and Noven Pharmaceuticals, Inc.
The transmucosal drug delivery systems market is expected to be valued at US$ 129.46 billion in 2031.
The transmucosal drug delivery systems market, by systems, is bifurcated into nasopulmonary, buccal & sublingual, vaginal, and others. The nasopulmonary segment held a larger market share in 2023.
The List of Companies - Transmucosal Drug Delivery Systems Market
- Teva Pharmaceutical Industries Ltd
- Cigna Corporation
- BioDelivery Sciences International, Inc
- 3M
- Henkel Finland Oy
- GlaxoSmithKline plc
- Aquestive Therapeutics, Inc
- Camurus AB
- Ximedica
- Noven Pharmaceuticals, Inc
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Related Reports
Mar 2024
Aquatic Veterinary Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type (Diagnostics and Treatments), Species (Fish, Crustaceans, Mollusca, and Others), Disease Source (Bacteria, Viruses, Parasites, and Others), Route of Administration (Water Medication, Medicated Feed, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Mar 2024
Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis By Treatment (Generic Drugs and Originators), Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
Mar 2024
Malaria and Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Treatment [Malaria and Sickle Cell Disease (SCD)], Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
Mar 2024
Pharmaceutical Contract Sales Organizations Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Services (Commercial Services and Non-Commercial Services), Modules (Syndicated Modules and Dedicated Modules), Therapeutic Area (Cardiovascular Disorders, Oncology, Metabolic Disorders, Neurology, Orthopedic Diseases, Infectious Diseases, and Others), End User (Biopharmaceutical Companies and Pharmaceutical Companies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Mar 2024
Breast Cancer Therapeutics Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Drug Therapy [Targeted Drug Therapy (Abemaciclib, Ado-Trastuzumab Emtansine, Palbociclib, Trastuzumab, and Other Target Drug Therapies), Hormonal Drug Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, and Selective Estrogen Receptor Downregulators), Chemotherapy, and Immunotherapy/Biological Therapy], Breast Cancer Type (Hormone Receptor, HER2+, and Triple-Negative Breast Cancer), Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, and Online Pharmacies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Mar 2024
Radioactive Tracer Market
Size and Forecast to 2030 - Global Analysis by Tracer Type [Technetium-99m & Tc-97m, Iodine-131, Iron-59, Lutetium-171, Rubidium (Rb-82) Chloride & Ammonia (N-13), Scandium-46, Seaborgium-269, Hassium-269, Gallium Citrate Ga 67, Prostate-Specific Membrane Antigen (PSMA) (Ga-68), FDDNP (F-18) & FDOPA (F-18), Phosphorus-32 & Chromium-51, Thallium-201, F-18 FDG, F-18 FAPI, Ga-68 FAPI, F-18 PSMA, DOTATOC/DOTANOC/DOTATATE (Ga-68), and Others], Test Type (PET, SPECT, and Others), Application (Oncology, Pulmonary, Neurology, Cardiology, and Others) End User (Hospitals & Clinics, Diagnostic Centers, Academic & Research Institutes, And Others), and Geography
Mar 2024
Glioma Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Disease (Astrocytoma, Oligoastrocytoma, and Oligodendroglioma), Treatment Type (Surgery, Chemotherapy, Radiation Therapy, and Others), Grade (Low Grade and High Grade), End User (Hospital & Clinics and Ambulatory Surgical Center), and Geography
Mar 2024
Hyperpigmentation Disorder Treatment Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Treatment Type (Cosmeceutical, Light or Laser Therapy, Microdermabrasion, Chemical Peels, Cryotherapy, and Others), Condition (Melasma, Solar Lentigines, Post-Inflammatory Hyperpigmentation, and Others), End User (Hospitals, Dermatology Centers, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)